nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.02.2007 | Original Paper

Infrequent mutation of ATBF1 in human breast cancer

verfasst von: Xiaodong Sun, Yingfa Zhou, Kristen B. Otto, Mingrong Wang, Ceshi Chen, Wei Zhou, Krithika Subramanian, Paula M. Vertino, Jin-Tang Dong

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Deletion at chromosome 16q is frequent in prostate and breast cancers, suggesting the existence of one or more tumor suppressor genes in 16q. Recently, the transcription factor ATBF1 at 16q22 was identified as a strong candidate tumor suppressor gene in prostate cancer, and loss of ATBF1 expression was associated with poorer prognosis in breast cancer. In the present study, we examined mutation, expression, and promoter methylation of ATBF1 in 32 breast cancer cell lines. Only 2 of the 32 cancer cell lines had mutations, although 18 nucleotide polymorphisms were detected. In addition, 24 of 32 (75%) cancer cell lines had reduced ATBF1 mRNA levels, yet promoter methylation was not involved in gene silencing. These findings suggest that ATBF1 plays a role in breast cancer through transcriptional downregulation rather than mutations.

Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, Cornelisse C (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13:1919–1925PubMed

Bieche I, Lidereau R (1995) Genetic alterations in breast cancer. Genes Chromosomes Cancer 14:227–251PubMed

Callen DF, Crawford J, Derwas C, Cleton-Jansen AM, Cornelisse CJ, Baker E (2002) Defining regions of loss of heterozygosity of 16q in breast cancer cell lines. Cancer Genet Cytogenet 133:76–82CrossRefPubMed

Chen C, Bhalala HV, Qiao H, Dong JT (2002) A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21:6567–6572CrossRefPubMed

Cleton-Jansen AM (2002) E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 4:5–8CrossRefPubMed

Cowin P, Rowlands TM, Hatsell SJ (2005) Cadherins and catenins in breast cancer. Curr Opin Cell Biol 17:499–508CrossRefPubMed

Gronwald J, Jauch A, Cybulski C, Schoell B, Bohm-Steuer B, Lener M, Grabowska E, Gorski B, Jakubowska A, Domagala W, Chosia M, Scott RJ, Lubinski J (2005) Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization. Int J Cancer 114:230–236CrossRefPubMed

Kaspar P, Dvorakova M, Kralova J, Pajer P, Kozmik Z, Dvorak M (1999) Myb-interacting protein, ATBF1, represses transcriptional activity of Myb oncoprotein. J Biol Chem 274:14422–14428CrossRefPubMed

Kataoka H, Miura Y, Joh T, Seno K, Tada T, Tamaoki T, Nakabayashi H, Kawaguchi M, Asai K, Kato T, Itoh M (2001) Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1. Oncogene 20:869–873CrossRefPubMed

Kataoka H, Bonnefin P, Vieyra D, Feng X, Hara Y, Miura Y, Joh T, Nakabayashi H, Vaziri H, Harris CC, Riabowol K (2003) ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res 63:5785–5792PubMed

Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkanen M, Varis A, Wasenius VM, Wolf M, Zhu Y (1999) DNA copy number losses in human neoplasms. Am J Pathol 155:683–694PubMed

Miura Y, Kataoka H, Joh T, Tada T, Asai K, Nakanishi M, Okada N, Okada H (2004) Susceptibility to killer T cells of gastric cancer cells enhanced by Mitomycin-C involves induction of ATBF1 and activation of p21 (Waf1/Cip1) promoter. Microbiol Immunol 48:137–145PubMed

Morinaga T, Yasuda H, Hashimoto T, Higashio K, Tamaoki T (1991) A human alpha-fetoprotein enhancer-binding protein, ATBF1, contains four homeodomains and seventeen zinc fingers. Mol Cell Biol 11:6041–6049PubMed

Rakha EA, Armour JA, Pinder SE, Paish CE, Ellis IO (2005) High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry. Int J Cancer 114:720–729CrossRefPubMed

Shibata Y, Miura Y, Tada T, Otsuka T, Asai K, Kato T, Matsui N (2001) Functional analysis of ATBF1, a multiple-homeodomain zinc finger protein, using lung cancer cell line A549. Nagoya Med J 45:31

Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, Miura Y, Simons JW, Dong JT (2005) Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 37:407–412CrossRefPubMed

Vos CB, ter Haar NT, Rosenberg C, Peterse JL, Cleton-Jansen AM, Cornelisse CJ, van de Vijver MJ (1999) Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer 81:1410–1418CrossRefPubMed

Watanabe A, Hippo Y, Taniguchi H, Iwanari H, Yashiro M, Hirakawa K, Kodama T, Aburatani H (2003) An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 63:8629–8633PubMed

van Wezel T, Lombaerts M, van Roon EH, Philippo K, Baelde HJ, Szuhai K, Cornelisse CJ, Cleton-Jansen AM (2005) Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res 7:R998–R1004CrossRefPubMed

Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21:5462–5482CrossRefPubMed

Yasuda H, Mizuno A, Tamaoki T, Morinaga T (1994) ATBF1, a multiple-homeodomain zinc finger protein, selectively down-regulates AT-rich elements of the human alpha-fetoprotein gene. Mol Cell Biol 14:1395–1401PubMed

Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Kawaguchi M, Miura Y, Iwase H (2005) ATBF1–a messenger RNA expression is correlated with better prognosis in breast cancer. Clin Cancer Res 11:193–198PubMed

Titel: Infrequent mutation of ATBF1 in human breast cancer
verfasst von: Xiaodong Sun
Yingfa Zhou
Kristen B. Otto
Mingrong Wang
Ceshi Chen
Wei Zhou
Krithika Subramanian
Paula M. Vertino
Jin-Tang Dong
Publikationsdatum: 01.02.2007
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2007
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-006-0148-y

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Infrequent mutation of ATBF1 in human breast cancer

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro

Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma

High-density oligonucleotide microarrays and functional network analysis reveal extended lung carcinogenesis pathway maps and multiple interacting genes in NNK [4-(methylnitrosamino)-1-(3-pyridyle)-1-butanone] induced CD1 mouse lung tumor

Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients

Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis

Analysis of gene expression identifies candidate molecular markers in nasopharyngeal carcinoma using microdissection and cDNA microarray

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie